Microbion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of Pravibismane
BOZEMAN, MT, and VANCOUVER, BC, Oct. 4, 2022 /PRNewswire/ - Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued to Microbion, United States Patent No.
- BOZEMAN, MT, and VANCOUVER, BC, Oct. 4, 2022 /PRNewswire/ - Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued to Microbion, United States Patent No.
- 11,324,715 on May 10, 2022, with claims to a pharmaceutical composition of pravibismane.
- The patent, titled "Bismuth-thiol compositions and methods for treating wounds," adds to Microbion's growing portfolio of intellectual property on the pravibismane program with this latest patent providing protection through to 2039.
- "We are pleased that the USPTO has granted this new patent that provides additional protection for the pravibismane program," said Karim Lalji, CEO of Microbion Pharma Corp. "This new patent with granted pharmaceutical composition claims is a key patent in our growing patent portfolio."